The experience of use of Fulvestrant (Faslodex) in the treatment of metastatic breast cancer
34 patients suffered from metastatic breast cancer were treated with Fulvestrant in outpatient department of Sverdlovsk Regional Oncology Dispensary since October 2012 till June 2015. Clinical response (full, partial or stabilization) was 79,4%. Median time to progression reach 9 months. Fulvestrant being well-tolerated was effective even after several regimens of chemotherapy and hormone therapy.